Here's What Key Metrics Tell Us About VAREX IMAGING (VREX) Q3 Earnings

VAREX IMAGING (VREX) reported robust Q3 2025 earnings, with EPS of $0.18 significantly surpassing the $0.04 consensus estimate by 350%, and revenue of $203 million exceeding the $190.2 million consensus despite a 2.9% year-over-year decline. Both the Industrial and Medical segments outperformed analyst expectations for revenue and gross profit. However, the stock has declined 16.5% over the past month, notably underperforming the S&P 500, suggesting a potential disconnect between recent operational strength and market sentiment.

Analysis

VAREX IMAGING (VREX) reported a notably strong Q3 2025 from a profitability perspective, with earnings per share of $0.18 dramatically exceeding the consensus estimate of $0.04 by 350% and improving from $0.14 in the prior-year quarter. Total revenue of $203 million also surpassed the $190.2 million estimate by 6.73%, although this figure represents a 2.9% year-over-year decline. A closer look at the segments reveals a divergence in performance: the Industrial segment grew revenues by 0.7% year-over-year to $60.9 million, while the larger Medical segment contracted by 4.4% to $142.1 million. Despite this top-line weakness in Medical, both segments beat analyst expectations on revenue and gross profit, indicating robust operational execution and margin control. This positive operational picture starkly contrasts with the stock's recent market performance, which saw a -16.5% return over the past month, significantly underperforming the S&P 500 composite. The current Zacks Rank #3 (Hold) suggests an expectation of in-line market performance, adding another layer to the disconnect between fundamental results and current investor sentiment.

Key Decisions for Investors

• Investors should scrutinize the significant divergence between VAREX's strong bottom-line beat and its severe stock underperformance, as this could present a value opportunity if the market is overly focused on the modest year-over-year revenue decline.
• Given the Medical segment's 4.4% revenue contraction, it is critical to monitor management's forward-looking guidance for this division to assess whether the decline is a temporary setback or a persistent trend.
• Consider the outperformance in both the Industrial and Medical segments against analyst estimates as a sign of operational strength, but weigh this against the negative market sentiment and the stock's 'Hold' rating before initiating or adding to a position.